Clinical research company IQVIA (NYSE: IQV) in Q4 CY2024, with sales up 2.3% year on year to $3.96 billion. On the other hand ...

Q4 2024 Earnings Call Transcript February 6, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $3.12, ...

IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 12.3% in the 4th quarter, according to the company in its most recent ...

DAVENPORT & Co LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 88.4% during the 4th quarter, ...

Baird raised the firm’s price target on Iqvia (IQV) to $220 from $210 and keeps a Neutral rating on the shares. The firm updated its model ...

Deutsche Bank raised the firm’s price target on Iqvia (IQV) to $260 from $250 and keeps a Buy rating on the shares following the “solid” Q4 ...

IQVIA reaffirms its 2025 outlook, projecting up to $16.13 billion in revenue and EPS of $11.70-$12.10. Strong TAS growth and ...

Shares of IQVIA Holdings Inc. IQV rallied 2.20% to $209.96 Thursday, on what proved to be an all-around mixed trading session ...

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, ...

Clinical research company IQVIA (NYSE: IQV) will be announcing earnings results tomorrow before market hours. Here’s what to ...

Feb 6 (Reuters) - Contract research firm IQVIA Holdings (IQV.N), opens new tab beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare ...